Administration-time-dependency of the pharmacokinetic behavior and therapeutic effect of a once-a-day theophylline in asthmatic children

M. H. Smolensky, P. H. Scott, R. B. Harrist, P. H. Hiatt, T. K. Wong, John Baenziger, B. J. Klank, A. Marbella, A. Meltzer

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Using a double-blind, placebo-control, crossover study design, 8 asthmatic children (8-15 years) were evaluated for temporal patterns in airways function throughout separate study periods when treatment was placebo or Theo-24® once-daily on separate occasions at 0600, 1500 or 2100 hr. During 39-hr in-hospital observations, pulmonary function and serum theophylline concentrations (STC) were assessed every 3 hr under all treatments. The pharmacokinetics of Theo-24® varied greatly depending on the dosing time. For the afternoon and evening dosings, the CmaxTmax, AUC1%swing,%fluctuation,%AUC fluctuation,%nocturnal excess and Cav(2,6hr)were all statistically significantly greater than for the morning dosing. Compared with the placebo regimen, dosing patients with Theo-24® at 1500 hr disrupted circadian patterns of airways function, especially airways patency, while dosing at 2100 hr, reduced the amplitude and shifted the acrophase of several spirometric measures to a slightly earlier time. Theo-24® treatment irrespective of dosing time resulted in comparable enhancement of the group24-hr mean, minimum and maximum values of airways patency with reference to placebo baselines. Theo-24® dosing at 1500 or 2100 hr, however, resulted in the best effect on the airways as assessed by the 24-hr mean FEV1.0level in 7 of the 8 asthmatic children. When the drug was given at 1500 hr, the time of lowest FEV1.0was shifted from the nighttime hours in 5 of 8 patients. These Findings suggest that clinicians need to individualize the theophylline dosing schedule of patients to best control the symptoms of asthma.

Original languageEnglish
Pages (from-to)435-447
Number of pages13
JournalChronobiology International
Volume4
Issue number3
DOIs
StatePublished - 1987

Fingerprint

theophylline
Therapeutic Uses
Theophylline
pharmacokinetics
placebos
Pharmacokinetics
therapeutics
Placebos
lung function
asthma
Cross-Over Studies
signs and symptoms (animals and humans)
experimental design
drugs
Area Under Curve
Appointments and Schedules
Therapeutics
Asthma
Lung
Serum

Keywords

  • Asthma
  • Children
  • Chrono-pharmacology
  • Once-a-day theophylline
  • Pharmacodynamics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Agricultural and Biological Sciences (miscellaneous)

Cite this

Administration-time-dependency of the pharmacokinetic behavior and therapeutic effect of a once-a-day theophylline in asthmatic children. / Smolensky, M. H.; Scott, P. H.; Harrist, R. B.; Hiatt, P. H.; Wong, T. K.; Baenziger, John; Klank, B. J.; Marbella, A.; Meltzer, A.

In: Chronobiology International, Vol. 4, No. 3, 1987, p. 435-447.

Research output: Contribution to journalArticle

Smolensky, M. H. ; Scott, P. H. ; Harrist, R. B. ; Hiatt, P. H. ; Wong, T. K. ; Baenziger, John ; Klank, B. J. ; Marbella, A. ; Meltzer, A. / Administration-time-dependency of the pharmacokinetic behavior and therapeutic effect of a once-a-day theophylline in asthmatic children. In: Chronobiology International. 1987 ; Vol. 4, No. 3. pp. 435-447.
@article{d75337401ea14d8580a647821f54b276,
title = "Administration-time-dependency of the pharmacokinetic behavior and therapeutic effect of a once-a-day theophylline in asthmatic children",
abstract = "Using a double-blind, placebo-control, crossover study design, 8 asthmatic children (8-15 years) were evaluated for temporal patterns in airways function throughout separate study periods when treatment was placebo or Theo-24{\circledR} once-daily on separate occasions at 0600, 1500 or 2100 hr. During 39-hr in-hospital observations, pulmonary function and serum theophylline concentrations (STC) were assessed every 3 hr under all treatments. The pharmacokinetics of Theo-24{\circledR} varied greatly depending on the dosing time. For the afternoon and evening dosings, the CmaxTmax, AUC1{\%}swing,{\%}fluctuation,{\%}AUC fluctuation,{\%}nocturnal excess and Cav(2,6hr)were all statistically significantly greater than for the morning dosing. Compared with the placebo regimen, dosing patients with Theo-24{\circledR} at 1500 hr disrupted circadian patterns of airways function, especially airways patency, while dosing at 2100 hr, reduced the amplitude and shifted the acrophase of several spirometric measures to a slightly earlier time. Theo-24{\circledR} treatment irrespective of dosing time resulted in comparable enhancement of the group24-hr mean, minimum and maximum values of airways patency with reference to placebo baselines. Theo-24{\circledR} dosing at 1500 or 2100 hr, however, resulted in the best effect on the airways as assessed by the 24-hr mean FEV1.0level in 7 of the 8 asthmatic children. When the drug was given at 1500 hr, the time of lowest FEV1.0was shifted from the nighttime hours in 5 of 8 patients. These Findings suggest that clinicians need to individualize the theophylline dosing schedule of patients to best control the symptoms of asthma.",
keywords = "Asthma, Children, Chrono-pharmacology, Once-a-day theophylline, Pharmacodynamics, Pharmacokinetics",
author = "Smolensky, {M. H.} and Scott, {P. H.} and Harrist, {R. B.} and Hiatt, {P. H.} and Wong, {T. K.} and John Baenziger and Klank, {B. J.} and A. Marbella and A. Meltzer",
year = "1987",
doi = "10.3109/07420528709083532",
language = "English",
volume = "4",
pages = "435--447",
journal = "Annual Review of Chronopharmacology",
issn = "0743-9539",
publisher = "Marcel Dekker Inc.",
number = "3",

}

TY - JOUR

T1 - Administration-time-dependency of the pharmacokinetic behavior and therapeutic effect of a once-a-day theophylline in asthmatic children

AU - Smolensky, M. H.

AU - Scott, P. H.

AU - Harrist, R. B.

AU - Hiatt, P. H.

AU - Wong, T. K.

AU - Baenziger, John

AU - Klank, B. J.

AU - Marbella, A.

AU - Meltzer, A.

PY - 1987

Y1 - 1987

N2 - Using a double-blind, placebo-control, crossover study design, 8 asthmatic children (8-15 years) were evaluated for temporal patterns in airways function throughout separate study periods when treatment was placebo or Theo-24® once-daily on separate occasions at 0600, 1500 or 2100 hr. During 39-hr in-hospital observations, pulmonary function and serum theophylline concentrations (STC) were assessed every 3 hr under all treatments. The pharmacokinetics of Theo-24® varied greatly depending on the dosing time. For the afternoon and evening dosings, the CmaxTmax, AUC1%swing,%fluctuation,%AUC fluctuation,%nocturnal excess and Cav(2,6hr)were all statistically significantly greater than for the morning dosing. Compared with the placebo regimen, dosing patients with Theo-24® at 1500 hr disrupted circadian patterns of airways function, especially airways patency, while dosing at 2100 hr, reduced the amplitude and shifted the acrophase of several spirometric measures to a slightly earlier time. Theo-24® treatment irrespective of dosing time resulted in comparable enhancement of the group24-hr mean, minimum and maximum values of airways patency with reference to placebo baselines. Theo-24® dosing at 1500 or 2100 hr, however, resulted in the best effect on the airways as assessed by the 24-hr mean FEV1.0level in 7 of the 8 asthmatic children. When the drug was given at 1500 hr, the time of lowest FEV1.0was shifted from the nighttime hours in 5 of 8 patients. These Findings suggest that clinicians need to individualize the theophylline dosing schedule of patients to best control the symptoms of asthma.

AB - Using a double-blind, placebo-control, crossover study design, 8 asthmatic children (8-15 years) were evaluated for temporal patterns in airways function throughout separate study periods when treatment was placebo or Theo-24® once-daily on separate occasions at 0600, 1500 or 2100 hr. During 39-hr in-hospital observations, pulmonary function and serum theophylline concentrations (STC) were assessed every 3 hr under all treatments. The pharmacokinetics of Theo-24® varied greatly depending on the dosing time. For the afternoon and evening dosings, the CmaxTmax, AUC1%swing,%fluctuation,%AUC fluctuation,%nocturnal excess and Cav(2,6hr)were all statistically significantly greater than for the morning dosing. Compared with the placebo regimen, dosing patients with Theo-24® at 1500 hr disrupted circadian patterns of airways function, especially airways patency, while dosing at 2100 hr, reduced the amplitude and shifted the acrophase of several spirometric measures to a slightly earlier time. Theo-24® treatment irrespective of dosing time resulted in comparable enhancement of the group24-hr mean, minimum and maximum values of airways patency with reference to placebo baselines. Theo-24® dosing at 1500 or 2100 hr, however, resulted in the best effect on the airways as assessed by the 24-hr mean FEV1.0level in 7 of the 8 asthmatic children. When the drug was given at 1500 hr, the time of lowest FEV1.0was shifted from the nighttime hours in 5 of 8 patients. These Findings suggest that clinicians need to individualize the theophylline dosing schedule of patients to best control the symptoms of asthma.

KW - Asthma

KW - Children

KW - Chrono-pharmacology

KW - Once-a-day theophylline

KW - Pharmacodynamics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0023583978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023583978&partnerID=8YFLogxK

U2 - 10.3109/07420528709083532

DO - 10.3109/07420528709083532

M3 - Article

VL - 4

SP - 435

EP - 447

JO - Annual Review of Chronopharmacology

JF - Annual Review of Chronopharmacology

SN - 0743-9539

IS - 3

ER -